On April 21, 2016 Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, reported that clinical data for its lead drug candidate CB-839, the Company’s novel, orally bioavailable glutaminase inhibitor, will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper), which is being held from June 3 to June 7, 2016 in Chicago, Illinois (Press release, Calithera Biosciences, APR 21, 2016, View Source;p=RssLanding&cat=news&id=2159182 [SID:1234511237]). Clinical results to be presented include data from Calithera’s Phase I combination trial in solid tumors. Calithera will hold an investor and analyst briefing Monday, June 6, 2016, in Chicago, Illinois at 6:30 p.m. CT. The meeting will be webcast live and available for replay for 30 days at www.calithera.com under the Investors section.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase in combination with paclitaxel in patients with triple negative breast cancer.
Abstract #1011
Presenter: Angela DeMichele, MD, MSCE, University of Pennsylvania
Date: June 5, 2016
Poster Display: 8:00 a.m. – 11:30 a.m. CT, Hall A, Board #116, Breast Cancer—Triple-Negative/ Cytotoxics/ Local Therapy
Poster Discussion: 4:45 p.m. – 6:00 p.m. CT, Hall D2
Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, alone and in combination with everolimus in patients with renal cell cancer.
Abstract #4568
Presenter: Funda Meric-Benstam, MD, University of Texas MD Anderson Cancer Center
Date: June 6, 2016
Poster Display: 1:00 p.m. – 4:30 p.m. CT, Hall A, Board #190, Genitourinary (Nonprostate)